HomeCONCORDBIO • NSE
add
Concord Biotech Ltd
Previous close
₹1,667.10
Day range
₹1,650.10 - ₹1,675.30
Year range
₹900.05 - ₹1,725.00
Market cap
173.45B INR
Avg Volume
97.46K
P/E ratio
57.65
Dividend yield
-
Primary exchange
NSE
Market news
Financials
Income Statement
Revenue
Net income
| (INR) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 2.41B | 0.05% |
Operating expense | 1.01B | 8.56% |
Net income | 775.73M | 0.26% |
Net profit margin | 32.22 | 0.22% |
Earnings per share | 7.41 | — |
EBITDA | 1.06B | -4.11% |
Effective tax rate | 24.76% | — |
Balance Sheet
Total assets
Total liabilities
| (INR) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.25B | — |
Total assets | — | — |
Total liabilities | — | — |
Total equity | 13.54B | — |
Shares outstanding | 104.69M | — |
Price to book | 12.89 | — |
Return on assets | — | — |
Return on capital | 16.77% | — |
Cash Flow
Net change in cash
| (INR) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 775.73M | 0.26% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation based biopharmaceutical active pharmaceutical ingredients sold worldwide.
Concord was founded in 2000 by Sudhir Vaid. It manufactures over 30 products across therapy segments such as immunosuppressant, oncology, antifungal, and antibacterial. It was the first company in India and the second in the world to develop an anti-immuno suppressant tacrolimus. Its manufacturing facility in Ahmedabad is approved by global regulatory bodies including Food and Drug Administration and Good manufacturing practice.
Quadria Capital acquired a 20% stake in Concord Biotech in 2016. Rakesh Jhunjhunwala's Rare Enterprises holds 24% stake in Concord. Wikipedia
Founded
2000
Website
Employees
1,180
